Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HTG Molecular Diagnostics, Inc. HTGM NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
23/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$0.17
-65.3%

HTG Molecular Diagnostics, Inc. (HTGM) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.48. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is HTGM = $0 (-65.3% upside).

Financials: revenue is $6M, -26.6%/yr average growth. Net income is $22M (loss), growing at -5.4%/yr. Net profit margin is -339.2% (negative). Gross margin is 28.2% (-25.4 pp trend).

Balance sheet: total debt is $5M against $5M equity (Debt-to-Equity (D/E) ratio 0.9, moderate). Current ratio is 1.89 (strong liquidity). Debt-to-assets is 27.2%. Total assets: $18M.

Analyst outlook: 8 / 8 analysts rate HTGM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 14/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$0.17
▼ 64.58% Downside
Average Price Target
The 12-month price target for HTG Molecular Diagnostics, Inc. is $0.17.

HTGM SharesGrow Score Overview

27/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 14/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HTGM

✗
VALUE Fail
10/100
HTGM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
HTGM: -26.6%/yr revenue is, -5.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet HTGM: Debt-to-Equity (D/E) ratio 0.9 (moderate), Current ratio is 1.89 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
14/100
HTGM: Gross margin is 28.2% (-25.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 14/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 8 / 8 analysts rate HTGM as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HTGM: Net profit margin is -339.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.462-24.96
Volume725.43K
Avg Volume (30D)253.92K
Market Cap$1.06M
Beta (1Y)0.99
Share Statistics
EPS (TTM)-24.28
Shares Outstanding$889.28K
IPO Date2015-05-06
Employees53
CEOJohn L. Lubniewski
Financial Highlights & Ratios
Revenue (TTM)$6.37M
Gross Profit$1.79M
EBITDA$-20.14M
Net Income$-21.59M
Operating Income$-20.83M
Total Cash$12.21M
Total Debt$4.83M
Net Debt$-7.38M
Total Assets$17.78M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.17
Analyst Forecast
1Y Price Target$0.17
Target High$0.17
Target Low$0.17
Upside-65.3%
Rating ConsensusBuy
Analysts Covering8
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS40434H1041

Price Chart

Track all markets on TradingView
HTGM
HTG Molecular Diagnostics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
0.46 52WK RANGE 24.96

People Also View

GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 GENE
GENE
Genetic Technologies Limited
$0.77
+0.00%
 PRPO
PRPO
Precipio, Inc.
$28.50
+1.60%
 PMD
PMD
Psychemedics Corporation
$2.67
+100.00%
 BIAF
BIAF
bioAffinity Technologies, Inc.
$2.81
-11.64%
 IDXG
IDXG
Interpace Biosciences, Inc.
$2.20
-4.35%
 SQL
SQL
SeqLL Inc.
$6.60
-2.38%
 INBS
INBS
Intelligent Bio Solutions Inc.
$2.77
+12.60%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message